Increased incidental detection of clonal hematopoiesis and new considerations for mutations in myelodysplastic precursors herald improved precision medicine strategies.
Using tumor and matched normal sequence data generated for tens of thousands of cancer patients, the team identified mosaic cancer susceptibility in around one in 1,000 cases.
Using tumor sequencing variant data, investigators identified clonal hematopoiesis mutations in blood that appear to be linked to therapy-related neoplasm risk.
Stanford and Memorial Sloan Kettering researchers have developed a multi-modal and multi-timepoint biomarker approach to predict therapeutic benefit in lung cancer cases.
The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
Epic may also develop a liquid biopsy test combining the chromosomal instability biomarker with other markers to predict prostate cancer treatment response.
A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and were associated with lower response to aromatase inhibitors.
